Evidence map›Paper›PMID 40109742›Full record

ArticleACS pharmacology & translational science2025

Impact of Radiometal Chelates on In Vivo Visualization of Immune Checkpoint Protein Using Radiolabeled Affibody Molecules.

Vladimir Tolmachev, Eleftherios Papalanis, Ekaterina A Bezverkhniaia, Alia Hani Rosly, Anzhelika Vorobyeva, Anna Orlova, Matilda Carlqvist, Fredrik Y Frejd, Maryam Oroujeni

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. EfficientInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vladimir TolmachevDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID https://orcid.org/0000-0002-6122-1734
Eleftherios PapalanisDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID https://orcid.org/0009-0006-5340-8618
Ekaterina A BezverkhniaiaDepartment of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden.ORCID https://orcid.org/0000-0001-7699-5719
Alia Hani RoslyDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID https://orcid.org/0009-0004-3896-7628
Anzhelika VorobyevaDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID https://orcid.org/0000-0002-4778-3909
Anna OrlovaDepartment of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden.ORCID https://orcid.org/0000-0001-6120-2683
Matilda CarlqvistAffibody AB, 171 65 Solna, Sweden.
Fredrik Y FrejdDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Maryam OroujeniDepartment of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.ORCID https://orcid.org/0000-0003-2660-9837

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immune checkpoint protein B7-H3 (CD276) is overexpressed in various cancers and is an attractive target for the treatment of malignant tumors. Radionuclide molecular imaging of B7-H3 expression using engineered scaffold proteins such as Affibody molecules is a promising strategy for the selection of potential responders to B7-H3-targeted therapy. Feasibility of B7-H3 imaging was demonstrated using two

Identifiers

PMID40109742
PMCPMC11915182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.